Evaxion Biotech Valuation
| EVAX Stock | USD 1.19 0.11 8.46% |
Today, the firm appears to be undervalued. Evaxion Biotech AS shows a prevailing Real Value of $3.21 per share. The current price of the firm is $1.19. Our model computes the value of Evaxion Biotech AS from reviewing the firm fundamentals such as Operating Margin of (0.57) %, shares outstanding of 5.58 M, and Current Valuation of 10.12 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Evaxion Biotech's valuation include:
Price Book 103.0523 | Enterprise Value 10.1 M | Enterprise Value Ebitda (0.59) | Price Sales 2.3144 | Forward PE 3.5714 |
Undervalued
Today
Please note that Evaxion Biotech's price fluctuation is very risky at this time. Calculation of the real value of Evaxion Biotech AS is based on 3 months time horizon. Increasing Evaxion Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Evaxion Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Evaxion Stock. However, Evaxion Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.19 | Real 3.21 | Target 9.33 | Hype 1.24 |
The intrinsic value of Evaxion Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Evaxion Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Evaxion Biotech AS helps investors to forecast how Evaxion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Evaxion Biotech more accurately as focusing exclusively on Evaxion Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Evaxion Biotech's intrinsic value based on its ongoing forecasts of Evaxion Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Evaxion Biotech's closest peers.
Evaxion Biotech Cash |
|
Evaxion Valuation Trend
Analysing the historical paterns of Evaxion Biotech's enterprise value and its market capitalization is a good way to estimate and gauge the value of Evaxion Biotech AS over time and is usually enough for investors to make rational market timing decisions.
Evaxion Biotech Total Value Analysis
Evaxion Biotech AS is currently forecasted to have valuation of 10.12 M with market capitalization of 13.28 M, debt of 10.87 M, and cash on hands of 25.25 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Evaxion Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.12 M | 13.28 M | 10.87 M | 25.25 M |
Evaxion Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Evaxion Biotech has an asset utilization ratio of 0.57 percent. This suggests that the Company is making $0.005664 for each dollar of assets. An increasing asset utilization means that Evaxion Biotech AS is more efficient with each dollar of assets it utilizes for everyday operations.Evaxion Biotech Ownership Allocation
The market capitalization of Evaxion Biotech AS is $13.28 Million. Evaxion Biotech AS retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Evaxion Biotech Profitability Analysis
The company reported the previous year's revenue of 73 K. Net Loss for the year was (22.12 M) with profit before overhead, payroll, taxes, and interest of 0.About Evaxion Biotech Valuation
Our relative valuation model uses a comparative analysis of Evaxion Biotech. We calculate exposure to Evaxion Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Evaxion Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 72.9 K | 76.5 K | |
| Pretax Profit Margin | (282.51) | (296.64) | |
| Operating Profit Margin | (273.66) | (287.34) | |
| Net Loss | (272.77) | (286.41) | |
| Gross Profit Margin | 0.90 | 0.80 |
Evaxion Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 2.7 M | |
| Forward Price Earnings | 3.5714 |
Evaxion Biotech Current Valuation Indicators
Valuation refers to the process of determining the present value of Evaxion Biotech AS and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Evaxion we look at many different elements of the entity such as Evaxion's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Evaxion Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Evaxion Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Evaxion Biotech's worth.Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.